GlassScriptPhysician profile
Keegan T Murphy
NPI 1336615517
$4,562.31
in general payments reported to CMS, 2019-2025
40 companies · $2,206 in 2025
The $2,206 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,661 · 2022: $165 · 2023: $374 · 2024: $156 · 2025: $2,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $523.64 | 2021-2025 | |
| Ucb, INC. | $422.03 | 2025 | Rystiggo, Nayzilam, Briviact |
| Glaxosmithkline, LLC. | $355.85 | 2021-2023 | Trelegy Ellipta |
| Pfizer INC. | $314.83 | 2021-2025 | |
| Lilly USA, LLC | $269.51 | 2021-2025 | Kisunla, Zepbound, Mounjaro |
| Novo Nordisk INC | $244.28 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $189.19 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $188.97 | 2021-2025 | Wainua, Farxiga |
| Janssen Pharmaceuticals, INC | $138.76 | 2021 | |
| Lundbeck LLC | $128.08 | 2025 | Vyepti, Rexulti |
| Jazz Pharmaceuticals INC. | $124.93 | 2025 | |
| Neurelis, INC. | $118.19 | 2025 | Valtoco |
| Amgen INC. | $109.71 | 2021-2023 | Otezla, Repatha |
| Alexion Pharmaceuticals, INC. | $108.25 | 2025 | Ultomiris |
| Astellas Pharma US INC | $108.02 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keegan Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.